Login to Your Account



Aviragen stumbles on phase IIa efficacy in RSV but strong safety the bigger goal

By Marie Powers
News Editor

Thursday, February 2, 2017

Shares of Aviragen Therapeutics Inc. took a drubbing after the company reported following Wednesday's market close that its phase IIa study of BTA585 missed the primary endpoint.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription